Annual report pursuant to Section 13 and 15(d)

Stockholders' Deficit and Capitalization (Detail Textuals)

v3.19.1
Stockholders' Deficit and Capitalization (Detail Textuals) - USD ($)
 1 Months Ended 12 Months Ended
Feb. 16, 2018
Jan. 19, 2018
Dec. 31, 2018
Dec. 31, 2017
Equity [Line Items]        
Common stock, shares authorized     500,000,000 500,000,000
Aggregate gross proceeds     $ 900,000  
Emerald financing issuance costs     154,092  
Warrant liability, issuance costs     137,192  
Reduction to APIC from the issuance of common stock     $ 16,900  
Securities Purchase Agreement | Emerald Health Sciences Inc        
Equity [Line Items]        
Common stock issued 15,000,000 15,000,000    
Number of warrants issued 20,400,000 20,400,000    
Warrant exercise price $ 0.10 $ 0.10    
Common stock gross proceeds   $ 1,500,000    
Subsequent financing purchase price, description   The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald shall be issued additional shares in order to protect against anti-dilution.    
Term of warrants 5 years      
Securities Purchase Agreement | Emerald Health Sciences Inc | Accredited Investor        
Equity [Line Items]        
Common stock issued 2,500,000      
Number of warrants issued 3,400,000      
Warrant exercise price $ 0.10      
Common stock gross proceeds $ 1,750,000      
Term of warrants 5 years